Overview

The Efficacy of Using Tranexamic Acid to Reduce Blood Loss In Simultaneous Bilateral Total Knee Arthroplasty

Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
0
Participant gender:
All
Summary
A randomized, double-blind, single-center and controlled study comparing the efficacy and safety of intravenous administration of tranexamic acid to reduce blood loss in simultaneous bilateral total knee arthroplasty.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Yanzhao
Treatments:
Tranexamic Acid
Criteria
Inclusion Criteria:

- Adult patients who plan to undergo simultaneous primary total knee arthroplasty on
bilateral knee joint with a diagnosis of osteoarthritis or aseptic bone necrosis, but
not of rheumatoid arthritis;

- All patients who have normal preoperative platelet count, normal prothrombin time,
normal partial thromboplastin time, and normal international normalized ratio;

- The use of only balanced electrolyte solutions and/or albumin for plasma volume
restitution.

Exclusion Criteria:

- Allergy to tranexamic acid;

- Receiving warfarin or heparin; had a history of hemophilia, deep venous thrombosis,
pulmonary embolism, or renal impairment; or were pregnant;

- Patients with any cardiovascular problems (such as myocardiac infarction history,
atrial fibrillation, angina);

- Patients with thromboembolic disorders, or those exhibiting a deteriorating general
condition;

- Preoperative anemia (a hemoglobin value of <11 g/dL in females and <12 g/dL in males),
refusal of blood products;

- Preoperative use of anticoagulant therapy within five days before surgery,
fibrinolytic disorders requiring intraoperative antifibrinolytic treatment,
coagulopathy (as identified by a preoperative platelet count of <150,000/mm3, an
international normalized ratio of >1.4, or a prolonged partial thromboplastin time
[>1.4 times normal]).